KRATOM toxicity cases have surged nationwide over the decade, triggering severe clinical complications and acute hospitalizations. According to a comprehensive analysis of 8,919 poison center exposures from 2010 through 2023, kratom related incidents escalated from 19 annual cases to 1,242 cases. More than 72% of reported individuals required formal medical evaluation in healthcare facilities. Approximately 34% of all exposures resulted in hospital admission, and 44.5% of admitted patients required critical care management, demonstrating substantial acute morbidity. Adults accounted for 91% of cases, with males representing 69% of exposures.
The primary psychoactive alkaloids in kratom, mitragynine and 7-hydroxymitragynine, produce complex physiological responses. At lower doses, these compounds exert stimulant effects, whereas higher doses stimulate opioid receptors. Documented severe effects include seizures, coma, profound respiratory depression, and cardiac dysrhythmias. While preclinical models suggest a lower baseline risk of hypoventilation compared to traditional opioids, clinical ingestions can still produce naloxone responsive respiratory depression. Mitragynine additionally interacts with P-glycoprotein and inhibits cytochrome P450 enzymes 2D6 and 3A4, substantially heightening toxicity risks during co-ingestion with other medications or substances. Polysubstance use appeared in 39% of total poison center reports and was associated with a higher frequency of major life-threatening effects.
Fatal outcomes occurred in 174 reported cases, including 27 single-substance ingestions. Adjudicated single-substance deaths predominantly involved young males found unresponsive or in sudden cardiac arrest, often without identifiable prodromal warning signs, culminating in irreversible anoxic brain injury. Pediatric exposures, though less frequent, produced severe clinical manifestations including agitation, marked central nervous system depression, and neonatal withdrawal symptoms such as tremors, tachycardia, and respiratory distress. Because routine toxicological drug screens do not detect mitragynine, clinicians evaluating unexplained seizures, acute altered mental status, or sudden cardiovascular collapse should proactively consider kratom toxicity, investigate potential supplement use, and prepare for intensive supportive care.
Reference
Comstock G et al. Association between state-level kratom regulations and poison center-reported severe medical outcomes and healthcare use: A United States national analysis. Addiction. 2026.
Featured Image: Alongkorn on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
